Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review.
about
COST-EFFECTIVE OPTIONS FOR THE PREVENTION AND MANAGEMENT OF GASTROINTESTINAL AND LIVER DISEASE IN THE ASIA-PACIFIC REGION.UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population.Genetic biomarkers for hepatocellular cancer risk in a caucasian population.Association between pre-sarcopenia, sarcopenia, and bone mineral density in patients with chronic hepatitis C.Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence
P2860
Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Health Economic Evaluations of ...... atitis C: a Systematic Review.
@ast
Health Economic Evaluations of ...... atitis C: a Systematic Review.
@en
type
label
Health Economic Evaluations of ...... atitis C: a Systematic Review.
@ast
Health Economic Evaluations of ...... atitis C: a Systematic Review.
@en
prefLabel
Health Economic Evaluations of ...... atitis C: a Systematic Review.
@ast
Health Economic Evaluations of ...... atitis C: a Systematic Review.
@en
P2093
P1476
Health Economic Evaluations of ...... atitis C: a Systematic Review.
@en
P2093
Andreas Gerber-Grote
Gloria Hanke
Miriam Luhnen
Siw Waffenschmidt
P2888
P304
P356
10.1007/S40258-016-0253-2
P577
2016-06-21T00:00:00Z
P6179
1046263322